1 |
Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012 August 1; 1(5): 699-716.
|
2 |
Clinical pipeline report, company report or official report of Idera Pharmaceuticals (2011).
|
3 |
Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial. J Cancer Res Clin Oncol. 2014 Sep;140(9):1615-24.
|
4 |
Novel drugs targeting Toll-like receptors for antiviral therapy. Future Virol. 2014 September; 9(9): 811-829.
|
5 |
Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma. Cancer Discov. 2021 Mar 11;candisc.1546.2020.
|
6 |
Gut feeling: MicroRNA discriminators of the intestinal TLR9-cholinergic links. Int Immunopharmacol. 2015 Nov;29(1):8-14.
|
7 |
Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist. Antivir Ther. 2007;12(5):741-51.
|
8 |
CYT003, a TLR9 agonist, in persistent allergic asthma - a randomized placebo-controlled Phase 2b study. Allergy. 2015 Sep;70(9):1160-8.
|
9 |
Company report (Iderapharma)
|
10 |
Cationic lipid/DNA complexes (JVRS-100) combined with influenza vaccine (Fluzone ) increases antibody response, cellular immunity, and antigenically drifted protection. Vaccine. 2009 June 12; 27(29):3811-3820.
|
11 |
Beneficial modulation of the tumor microenvironment and generation of anti-tumor responses by TLR9 agonist lefitolimod alone and in combination with checkpoint inhibitors. Oncoimmunology. 2019 Sep 20;8(12):e1659096.
|
12 |
DOI: 10.1371/journal.pone.0087712
|
13 |
Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. Br J Haematol. 2009 August; 146(3): 282-291.
|
14 |
Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
|
15 |
Clinical pipeline report, company report or official report of dynavax.
|
16 |
Clinical pipeline report, company report or official report of Exicure.
|
17 |
Clinical pipeline report, company report or official report of Checkmate Pharmaceuticals.
|
18 |
Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus. Lupus Foundation of America, Inc. 2007.
|
19 |
Company report (Dynavax)
|
20 |
National Cancer Institute Drug Dictionary (drug id 662816).
|
21 |
URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1759).
|
22 |
Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019871)
|
23 |
Pfizer. Product Development Pipeline. March 31 2009.
|
24 |
Clinical pipeline report, company report or official report of Idera Pharmaceuticals.
|
25 |
Pharma & Vaccines. Product Development Pipeline. April 29 2009.
|
26 |
The novel TLR9 antagonist COV08-0064 protects from ischemia/reperfusion injury in non-steatotic and steatotic mice livers. Biochem Pharmacol. 2016 Jul 15;112:90-101.
|
27 |
Toll-like receptor 9 antagonism modulates astrocyte function and preserves proximal axons following spinal cord injury. Brain Behav Immun. 2019 Aug;80:328-343.
|
|
|
|
|
|
|